https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-28 / World J. Gastroenterol. 2019 Jun;25(24):2977-2989
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-28 / World J. Gastroenterol. 2019 Jun;25(24):2977-29892019-06-28 00:00:002019-06-28 00:00:00Immunotherapy for hepatocellular carcinoma: Current and future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-22 / Cancers (Basel) 2019 Jun;11(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-22 / Cancers (Basel) 2019 Jun;11(6)2019-06-22 00:00:002019-06-22 00:00:00Can Dendritic Cell Vaccination Prevent Leukemia Relapse?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-21 / J. Cell. Physiol. 2020 Jan;235(1):74-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-21 / J. Cell. Physiol. 2020 Jan;235(1):74-862019-06-21 00:00:002020-05-06 13:50:39Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-19 / Oncology 2019 Jun;:1-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-19 / Oncology 2019 Jun;:1-142019-06-19 00:00:002019-06-19 00:00:00Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-19 / PLoS ONE 2019;14(6):e0217894
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-19 / PLoS ONE 2019;14(6):e02178942019-06-19 00:00:002019-06-19 00:00:00The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)2019-06-17 11:50:402019-07-17 11:53:03Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-14 / Br J Clin Pharmacol 2019 Aug;85(8):1670-1683
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-14 / Br J Clin Pharmacol 2019 Aug;85(8):1670-16832019-06-14 00:00:002023-03-07 12:45:44Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-10 / Cancer Med 2019 Jun;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-10 / Cancer Med 2019 Jun;2019-06-10 00:00:002019-06-10 00:00:00Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-06 / Ther Apher Dial 2019 Jun;23(3):279-288
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-06 / Ther Apher Dial 2019 Jun;23(3):279-2882019-06-06 00:00:002019-06-06 00:00:00Phase I/II Pilot Study of Wilms‘ Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)2019-06-03 00:00:002020-08-26 12:15:23A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
